Rivian Automotive, Inc. vs Tilray Brands Inc — how do they compare? Rivian Automotive, Inc. trades at $16.03 (market cap $23.41B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Rivian Automotive, Inc. is far larger — about 39.6× Tilray Brands Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| RIVN | TLRY | |
|---|---|---|
Market Cap | $23.41B | $591.60M |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $21.00 |
52-Week Low | $12.50 | $3.88 |
Enterprise Value | $23.45B | $758.73M |
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.
RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →